CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies

CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies

T cell-recruiting bispecific antibodies (bsAbs) are successfully used for the treatment of cancer. However, effective treatment with bsAbs is so far hampered by severe side effects, i.e., potentially life-threatening cytokine release syndrome. Off-target T cell activation due to binding of bispecifi...

Full description

Bibliographic Details
Main Authors: Joseph Kauer, Fabian Vogt, Ilona Hagelstein, Sebastian Hörner, Melanie Märklin, Stefanie Maurer, Helmut R. Salih, Gundram Jung, Latifa Zekri
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
bispecific antibodies
cytokine release syndrome
CD18
immunotherapy
T cell activation
Online Access:https://www.mdpi.com/2072-6694/13/18/4596

Internet

https://www.mdpi.com/2072-6694/13/18/4596

Similar Items